Research progress of PD-1/PD-L1 in small cell lung cancer
10.3969/j.issn.1000-8179.2019.01.122
- VernacularTitle:PD-1/PD-L1在小细胞肺癌中的临床研究进展
- Author:
Tian HAO
1
;
Xiaoyan KANG
;
Haibo ZHU
;
Xia SONG
Author Information
1. 山西医科大学第二临床医学院
- Keywords:
small cell lung cancer;
programmed death-1 (PD-1);
programmed cell death-ligand 1 (PD-L1);
tumor mutation burden (TMB);
PD-L1 expression
- From:
Chinese Journal of Clinical Oncology
2019;46(1):44-48
- CountryChina
- Language:Chinese
-
Abstract:
Small-cell lung cancer (SCLC) has a high degree of malignancy and is characterized by strong invasiveness, rapid growth, and early metastasis. SCLC is sensitive to initial treatment with chemotherapy and radiotherapy, but it can easily relapse and has a poor prognosis. Both programmed death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) antagonists activate the immune response of tumor cells by activating T cells, and have shown exciting curative effects in clinical studies of SCLC, thereby becoming powerful po-tential agents to treat SCLC in the future. This article aims to illustrate the progress of PD-1/PD-L1 inhibitors in the treatment of SCLC, as well as the role of PD-L1 expression and tumor mutation burden (TMB) as a biomarker in SCLC.
